# Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

> **NCT01422720** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 72 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Eslicarbazepine Acetate

## Key facts

- **NCT ID:** NCT01422720
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01422720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01422720, "Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01422720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*